ePrints

Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease

Lookup NU author(s): Professor Azfar ZamanORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2025 The AuthorsBackground and Rationale: In-stent restenosis (ISR) remains the leading cause of treatment failure following percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. Especially in small caliber coronary arteries, restenosis is common following PCI and represents a treatment challenge. Drug-coated balloons (DCB) are an attractive alternative to stents for treatment of both ISR and small vessel disease. The safety and efficacy of the Prevail DCB will be assessed for (1) the treatment of ISR and (2) de novo lesions in small vessels. Trial Design: Prevail Global is a prospective, international, dual cohort clinical study enrolling (1) patients undergoing PCI for ISR in a randomized controlled trial (1:1) design comparing the Prevail DCB versus an FDA-approved DCB (AgentTM, Boston Scientific Corporation, Natick MA), and (2) patients with de novo small vessel disease undergoing PCI with the Prevail DCB as part of a single-arm study compared with a historical control. The primary endpoint is target lesion failure, defined as a composite of cardiac death, target vessel myocardial infarction, or clinically-driven target lesion revascularization at 12 months post procedure. Patient follow-up is planned for 1 month, 6 months, and yearly through 5 years. Enrollment is expected to start in early 2025. Conclusions: The Prevail Global study will directly assess the safety and efficacy of the Prevail DCB for the treatment of ISR and de novo small vessel lesions. Trial Registration: Prevail Global, NCT06535854, is registered at https://clinicaltrials.gov/study/NCT06535854.

Publication metadata

Author(s): Kandzari DE, Latib A, Mylotte D, Ali ZA, Zaman A, Brar S, Parke M, Scheller B

Publication type: Article

Publication status: Published

Journal: American Heart Journal

Year: 2025

Volume: 283

Pages: 26-36

Print publication date: 01/05/2025

Online publication date: 23/01/2025

Acceptance date: 18/01/2025

Date deposited: 03/03/2025

ISSN (print): 0002-8703

ISSN (electronic): 1097-6744

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.ahj.2025.01.010

DOI: 10.1016/j.ahj.2025.01.010

PubMed id: 39863032

Altmetrics

Funding

Share